Prabhleen (Sheena) Singh, MD
Professor of Medicine
University of California, San Diego
Featured in the Session: Unexplored Pathways of Residual Risk in Diabetic Kidney Disease to Find Novel Cures
When
Sunday, June 7
at 4:30 p.m.
Where
R07 (Level 2)
Ernest N. Morial Convention Center
What is your presentation about?
My presentation focuses on understanding the role of mitochondria in diabetes-related kidney disease. Kidneys are highly metabolic, and have a high oxygen requirement for energy generation to support transport of electrolytes in the kidney tubules. This energy generation is fueled by mitochondria and healthy mitochondria are essential to support the energy demand. Mitochondrial dysfunction has been shown to play an important role in the development and progression of kidney disease in diabetes. Our work shows the impact of new therapies such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists on kidney oxygenation and mitochondrial function. The presentation also discusses other novel and exciting therapies to address mitochondrial dysfunction in diabetes-related kidney disease.
How do you hope your presentation will impact diabetes research or care?
By understanding the mechanisms of mitochondrial dysfunction in diabetes-related kidney disease, I aim to identify specific targets and help in the development of therapies to halt or slow down the progression of kidney disease.
How did you become involved with this area of diabetes research or care?
Diabetes is the major cause of kidney disease in the U.S. and until recently there were limited options to treat diabetes-related kidney disease. Being a physician-scientist, I became interested in understanding the pathways that lead to diabetes-related kidney disease to help in the development of therapies for patients who I care for on a daily basis and are severely impacted by this condition.